Junjie Chen

Prof. Dr. Junjie Chen


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2018 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
HLHuaxiu Luo
Huaxiu Luo
CCChang Cao
Chang Cao
JZJian Zhong
Jian Zhong
JCJunjie Chen
Junjie Chen
YCYing Cen
Ying Cen

23 May 2025 in Science Advances
Verified
Journal Article
Open access
HSHaozhou Shu
Haozhou Shu
TZTaotian Zhang
Taotian Zhang
YJYilin Jiang
Yilin Jiang
ZDZhenkang Diao
Zhenkang Diao
YXYani Xu
Yani Xu
LLLing Ling
Ling Ling
It is essential to spatiotemporally control the microniche of wound at different healing stages for rapid and scarless healing. Hence, a multifunctional soft hydrogel integrated with programmed drug release capability (MLVgel) was fabricated. MLVgel is adhesive and moldable with low friction response, which provides moisture and responses to an infectious environment to deliver bactericidal and antioxidant effects in rat bacterial infection and burn wound models. By release control, instant short-term inflammation suppression is combined with sustained mechano-transduction signal inhibition. This dynamically modulates immune responses and delays En1 + fibroblast activation via the YAP-TEAD pathway, ultimately facilitating scarless wound regeneration. Genomic analyses showed that the enhanced reepithelization and mechanoregulation by MLVgel during different wound phases are indispensable for its therapeutic outcomes. Last, MLVgel resulted in markedly improved healing in a pig mature scar model, which demonstrated its translation potential. Our results also verified the necessity of programed dynamic regulation in the healing process.

1 October 2020 in The Breast
Verified
Journal Article
Open access
WWWilson A. Wijaya
Wilson A. Wijaya
JPJing Peng
Jing Peng
YHYinhai He
Yinhai He
JCJunjie Chen
Junjie Chen
YCYing Cen
Ying Cen
The axillary reverse mapping (ARM) technique, identify and preserve arm nodes during sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND), was developed to prevent breast-cancer related lymphedema (BCRL) remains controversial. A comprehensive search of Medline Ovid, Pubmed, Web of Science and the Cochrane CENTRAL databases was conducted from the inception till January 2020. The key word including “breast cancer”, “axillary reverse mapping”, and “lymphedema”. Stata 15.1 software was used for the meta-analysis. As a result, twenty-nine related studies involving 4954 patients met our inclusion criteria. The pooled overall estimate lymphedema incidence was 7% (95% CI 4%–11%, I2 = 90.35%, P < 0.05), with SLNB showed a relatively lower pooled incidence of lymphedema (2%, 95% CI 1%–3%), I2 = 26.06%, P = 0.23) than that of ALND (14%, 95% CI 5%–26%, I2 = 93.28%, P < 0.05) or SLNB and ALND combined (11%, 95% CI 1%–30%). The ARM preservation during ALND procedure could significantly reduce upper extremity lymphedema in contrast with ARM resection (OR = 0.27, 95% CI 0.20–0.36, I2 = 31%, P = 0.161). Intriguingly, the result favored ALND-ARM over standard-ALND in preventing lymphedema occurrence (OR = 0.21, 95% CI 0.14–0.31, I2 = 43%, P = 0.153). The risk of metastases in the ARM-nodes was not significantly lower in the patients who had received neoadjuvant chemotherapy, as compared to those without neoadjuvant treatment (OR = 1.20, 95% CI 0.74–1.94, I2 = 49.4%, P = 0.095). ARM was found to significantly reduce the incidence of BCRL. The selection of patients for this procedure should be based on their axillary nodal status. Preoperative neoadjuvant chemotherapy has no significant impact on the ARM lymph node metastasis rate.

10 June 2019 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
JWJunliang Wu
Junliang Wu
LFLu Fang
Lu Fang
YCYing Cen
Ying Cen
YQYong Qing
Yong Qing
JCJunjie Chen
Junjie Chen
ZLZhengyong Li
Zhengyong Li
A keloid is a benign fibroproliferative skin tumor that results from abnormal wound healing after injury and tends to grow beyond the boundary of the original wound; the mechanism of keloid formation is still unclear. MicroRNA-21 (MiR-21) is a representative microRNA that plays a key role in a variety of fibrotic diseases via the transforming growth factor-β/Smad signaling pathway. The aim of our study was to explore the mechanism of keloid formation. First, we found that the expression of miR-21 in keloids and keloid fibroblasts was significantly upregulated by microRNA microarray and real-time polymerase chain reaction. Additionally, at the protein level, our study confirmed that the overexpression of miR-21 could promote the process of keloid fibrosis to some extent and also indicated that a low expression of miR-21 could inhibit the process of keloid fibrosis. Finally, the results proved that miR-21 could participate in the keloid fibrosis process through negative regulation of its downstream target gene Smad7 via the transforming growth factor-β/Smad signaling pathway, which provides a guiding framework for further studies and new theoretical support for keloid clinical treatment.

17 March 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
QLQijie Li
Qijie Li
FCFengrui Cheng
Fengrui Cheng
KZKai Zhou
Kai Zhou
LFLu Fang
Lu Fang
JWJunliang Wu
Junliang Wu
YQYong Qing
Yong Qing
Hyperproliferation of fibroblasts is the main cause of keloid formation. However, the pathogenesis of keloids has yet to be fully elucidated. Tumor necrosis factor (TNF)‑α may play an important role in the formation and proliferation of keloids, as it is implicated in the pathogenesis of various fibrous disorders. In the present study, the expression level of TNF‑α and its receptors, soluble TNF receptor (sTNFR)1 and sTNFR2, in the peripheral blood and skin tissues was detected by ELISA, reverse transcription‑quantitative PCR or immunohistochemistry. There was no statistically significant difference in the expression of TNF‑α and sTNFR2 in the peripheral blood and skin tissues between patients with keloids and healthy participants (P>0.05), while the sTNFR1 mRNA level in fibroblasts cultured in vitro and its protein level in keloid skin samples were significantly higher compared with those in normal skin (P<0.05). Subsequently, TNF‑α recombinant protein was used to treat keloid‑derived and normal skin fibroblasts, and it was observed that TNF‑α promoted the proliferation of keloid fibroblasts (KFs), but had little effect on normal skin fibroblasts. Furthermore, it was observed that TNF‑α stimulation led to the activation of the nuclear factor (NF)‑κB, c‑Jun N‑terminal kinase (JNK) and p38 mitogen‑activated protein kinase (MAPK) pathways in KFs. In conclusion, KFs exhibited increased expression of sTNFR1, which may contribute to the increased sensitivity to TNF‑α, resulting in low concentrations of TNF‑α activating the NF‑κB, JNK and p38 MAPK pathways, thereby promoting the sustained and excessive proliferation of KFs.

30 April 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
JZJinjue Zhang
Jinjue Zhang
YWYixi Wang
Yixi Wang
WWWilson Adrian Wijaya
Wilson Adrian Wijaya
ZLZhongyao Liang
Zhongyao Liang
JCJunjie Chen
Junjie Chen